U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07299409) titled 'First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.' on June 19.
Brief Summary: The goal of this clinical trial is to learn if the drug Sacituzumab govitecan (SG) reduces disease progression when used as a first-line treatment in adults with advanced triple-negative breast cancer (TNBC) who have not received prior treatments in the advanced setting. It will also look at whether the effectiveness of the drug differs between TNBC adults with homologous recombination deficiency (HRD) subtypes and those with non-HRD subtypes. The main questions this study aims to answer are:
* Will patients wi...